BioCancell Therapeutics Inc., a biopharmaceuticals corporation, has developed Targeted Cancer Therapy for the treatment of numerous types of cancer. The treatment is based on utilizing a target gene, such as the H19 gene, an oncofetal gene expressed at high levels in over 40 types of human cancer tissues, while existing at a nearly undetectable level in the surrounding normal tissues.

BioCancell was founded in 2004 by Professor Avraham Hochberg, Professor of Molecular Biology at the Hebrew University of Jerusalem, Israel. Over the course of 20 years of technology development, millions of dollars in non-diluting grants have been invested directly in research performed by Prof. Hochberg's laboratory and directly in BioCancell, as well as millions more raised in private and public investment rounds.

BioCancell's lead product, a plasmid designated BC-819, is undergoing clinical testing for diverse cancer applications, including pancreatic cancer, superficial bladder carcinoma and ovarian cancer. Results to date have shown an excellent safety profile, combined with promising efficacy in improving the condition of cancer patients.